PMID- 16281981
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20060126
LR  - 20181113
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 3
DP  - 2005 Nov 10
TI  - CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma.
PG  - 41
AB  - A CD8+ cytotoxic T lymphocyte (CTL) line was derived from the peripheral blood 
      mononuclear cells of a patient with primary melanoma. The CD8+ CTL line 
      specifically lysed the autologous primary melanoma cells and not the natural 
      killer cell-sensitive K562 cells or lymphokine activated killer cell-sensitive 
      DAUDI cells. When a large panel of human leukocyte antigen (HLA)-matched and 
      -unmatched allogeneic melanoma, glioma, breast and colorectal carcinoma cells was 
      tested as targets in cytolysis assays, 4 HLA-matched and two HLA-unmatched 
      allogeneic metastatic melanoma lines were lysed by the CD8+ CTL. Lysis of 
      autologous and allogeneic melanoma cells was dependent on the effector-to-target 
      cell ratio. Lysis of autologous melanoma cells was not blocked by anti-HLA class 
      I or class II antibodies, confirming that the cytolytic activity of the CD8+ CTL 
      was HLA-unrestricted. CTL lysis of autologous melanoma cells was CD3 (T cell 
      receptor) dependent and FAS-FAS-L, and CD1 independent. Identification of the 
      melanoma-associated antigen recognized by the HLA-unrestricted CTL may provide a 
      vaccine for a broad population of melanoma patients.
FAU - Somasundaram, Rajasekharan
AU  - Somasundaram R
AD  - The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA. 
      shyam@wistar.org
FAU - Caputo, Laura
AU  - Caputo L
FAU - Guerry, DuPont
AU  - Guerry D
FAU - Herlyn, Dorothee
AU  - Herlyn D
LA  - eng
GR  - P01 CA025874/CA/NCI NIH HHS/United States
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - P50 CA093372/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20051110
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
PMC - PMC1308870
EDAT- 2005/11/12 09:00
MHDA- 2005/11/12 09:01
PMCR- 2005/11/10
CRDT- 2005/11/12 09:00
PHST- 2005/10/27 00:00 [received]
PHST- 2005/11/10 00:00 [accepted]
PHST- 2005/11/12 09:00 [pubmed]
PHST- 2005/11/12 09:01 [medline]
PHST- 2005/11/12 09:00 [entrez]
PHST- 2005/11/10 00:00 [pmc-release]
AID - 1479-5876-3-41 [pii]
AID - 10.1186/1479-5876-3-41 [doi]
PST - epublish
SO  - J Transl Med. 2005 Nov 10;3:41. doi: 10.1186/1479-5876-3-41.